Joint Clinical Assessment Poster Tour
Speaker(s)
Kejsi Begaj, PharmD, Center for Health Outcomes, Policy, and Economics, Rutgers University, New Brunswick, NJ, USA and Alin Kalayjian, PharmD, MBA, GSK, Somerset, NJ, USA
PT25 Potential for Standardization in Economic Assessment Across HTA Bodies: A Case Study in First-Line Treatments of Non-Small Cell Lung Cancer
PT26 From Clinical Assessment to Drug Reimbursement in Spain: Current Timelines and Potential Impact From the Joint Clinical Assessment
PT27 Time to Reimbursement in Ireland: Utilizing Regression Analysis to Assess Factors Contributing to Overall Timelines
PT28 Do We Say “Game Over” When OS Data Is Not Mature at Launch? A Review of Value Drivers for Oncology Products in the Absence of Significant OS Gains
PT29 From European Union Joint Clinical Assessments to Local Health Technology Assessments: An Environmental Scan of Methodological Guidance Across Key European Markets
PT30 Navigating the New European Member State Coordination Group on Health Technology Assessment Quantitative Evidence Synthesis Guidelines
Code
213